An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease.
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2013
At a glance
- Drugs MEDI 6012 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Coronary artery disease
- Focus Adverse reactions
- Sponsors AlphaCore Pharma
- 09 Oct 2012 Results have been reported in an AlphaCore Pharma media release.
- 09 Oct 2012 Primary safety endpoints have been met, according to an AlphaCore media release.
- 09 Oct 2012 Status changed from recruiting to completed, based on an AlphaCore Pharma media release.